Arginine reprograms metabolism in liver cancer via RBM39
Cell · 2023-11 · 186 (23) · 5068-5083.e23
DOI: 10.1016/j.cell.2023.09.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2023-11. Verfasst von Dirk Mossmann und 18 weiteren Autor:innen. Beteiligte Einrichtung: Biozentrum, University of Basel, 4056 Basel, Switzerland. Hauptthemen laut MEDLINE: Arginine, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 296-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Louis-Jeantet Foundation, Sjöbergstiftelsen.
Abstract (Originalsprache)
Metabolic reprogramming is a hallmark of cancer. However, mechanisms underlying metabolic reprogramming and how altered metabolism in turn enhances tumorigenicity are poorly understood. Here, we report that arginine levels are elevated in murine and patient hepatocellular carcinoma (HCC), despite reduced expression of arginine synthesis genes. Tumor cells accumulate high levels of arginine due to increased uptake and reduced arginine-to-polyamine conversion. Importantly, the high levels of arginine promote tumor formation via further metabolic reprogramming, including changes in glucose, amino acid, nucleotide, and fatty acid metabolism. Mechanistically, arginine binds RNA-binding motif protein 39 (RBM39) to control expression of metabolic genes. RBM39-mediated upregulation of asparagine synthesis leads to enhanced arginine uptake, creating a positive feedback loop to sustain high arginine levels and oncogenic metabolism. Thus, arginine is a second messenger-like molecule that reprograms metabolism to promote tumor growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biozentrum, University of Basel, 4056 Basel, Switzerland.
- Institute of Molecular Systems Biology, ETH Zürich, 8093 Zürich, Switzerland.
- Institute of Medical Genetics and Pathology, University Hospital Basel, 4031 Basel, Switzerland; Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.
- Department of Biomedicine, Hepatology Laboratory, University and University Hospital Basel, 4031 Basel, Switzerland.
- Institute of Medical Genetics and Pathology, University Hospital Basel, 4031 Basel, Switzerland.
- Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
Förderung
- European Research Council
- Louis-Jeantet Foundation
- Sjöbergstiftelsen
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Centro de Investigación e Innovación en Energía Marina
- Alexander von Humboldt-Stiftung
- NCCR Catalysis
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Mossmann, D., Müller, C., Park, S., Ryback, B., Colombi, M., Ritter, N., Weißenberger, D., Dazert, E., Coto-Llerena, M., Nuciforo, S., Blukacz, L., Ercan, C., Jimenez, V., Piscuoglio, S., Bosch, F., Terracciano, L. M., Sauer, U., Heim, M. H., & Hall, M. N. (2023). Arginine reprograms metabolism in liver cancer via RBM39. Cell, 186(23), 5068-5083.e23. https://doi.org/10.1016/j.cell.2023.09.011
Vancouver
Mossmann D, Müller C, Park S, Ryback B, Colombi M, Ritter N, et al. Arginine reprograms metabolism in liver cancer via RBM39. Cell. 2023;186(23):5068-5083.e23. doi:10.1016/j.cell.2023.09.011
BibTeX
@article{Mossmann2023,
author = {Mossmann, Dirk and Müller, Christoph and Park, Sujin and Ryback, Brendan and Colombi, Marco and Ritter, Nathalie and Weißenberger, Diana and Dazert, Eva and Coto-Llerena, Mairene and Nuciforo, Sandro and Blukacz, Lauriane and Ercan, Caner and Jimenez, Veronica and Piscuoglio, Salvatore and Bosch, Fatima and Terracciano, Luigi M and Sauer, Uwe and Heim, Markus H and Hall, Michael N},
title = {Arginine reprograms metabolism in liver cancer via RBM39},
journal = {Cell},
year = {2023},
volume = {186},
number = {23},
pages = {5068--5083.e23},
doi = {10.1016/j.cell.2023.09.011}
}
EUVIMED